Thomas A. Rado

1.1k total citations
34 papers, 942 citations indexed

About

Thomas A. Rado is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Thomas A. Rado has authored 34 papers receiving a total of 942 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 12 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Thomas A. Rado's work include Cystic Fibrosis Research Advances (8 papers), Neonatal Respiratory Health Research (8 papers) and Mycobacterium research and diagnosis (6 papers). Thomas A. Rado is often cited by papers focused on Cystic Fibrosis Research Advances (8 papers), Neonatal Respiratory Health Research (8 papers) and Mycobacterium research and diagnosis (6 papers). Thomas A. Rado collaborates with scholars based in United States, Canada and United Kingdom. Thomas A. Rado's co-authors include James K. Bubien, Joseph H. Bates, Raymond A. Frizzell, Robert W. Wallace, Jeffrey L. Ram, Frank B. Gelder, Robert Schoumacher, David R. Kelly, Kevin L. Kirk and Kathryn M. Stowell and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Thomas A. Rado

34 papers receiving 901 citations

Peers

Countries citing papers authored by Thomas A. Rado

Since Specialization

Citations

This map shows the geographic impact of Thomas A. Rado's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas A. Rado with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas A. Rado more than expected).

Fields of papers citing papers by Thomas A. Rado

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas A. Rado. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas A. Rado. The network helps show where Thomas A. Rado may publish in the future.

Co-authorship network of co-authors of Thomas A. Rado

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas A. Rado. A scholar is included among the top collaborators of Thomas A. Rado based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas A. Rado. Thomas A. Rado is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	World Health Organization Studies on Bacteriophage Typing of Mycobacteria 2015 ·American Review of Respiratory Disease ·Thomas A. Rado, Joseph H. Bates, H. W. B. Engel, E. Mankiewicz, (unknown), Y Mizuguchi, L Sŭla	3
2	Actions of H-Subunit Ferritin and Lactoferrin as Suppressor Molecules of Myelopoiesis in vitro and in vivo1 2015 ·Current studies in hematology and blood transfusion ·Hal E. Broxmeyer, Charlie Mantel, Patrick S. Gentile, C H Srivastava, Keisuke Miyazawa, James R. Zucali, Thomas A. Rado, Sonia Levi, Paolo Arosio	1
3	Axitinib and/or bevacizumab with modified FOLFOX‐6 as first‐line therapy for metastatic colorectal cancer: A randomized phase 2 study 2013 ·Cancer ·Jeffrey R. Infante, Tony R. Reid, Allen Lee Cohn, William J. Edenfield, Terrence P. Cescon, John Hamm, Imtiaz A. Malik, Thomas A. Rado, (unknown), Donald Richards, Jamal Tarazi, Brad Rosbrook, Sinil Kim, Thomas H. Cartwright	38
4	Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours 2012 ·British Journal of Cancer ·Lainie P. Martin, Mark Kozloff, Roy S. Herbst, Thomas A. Samuel, (unknown), Brad Rosbrook, Michael A. Tortorici, (unknown), Jamal Tarazi, Anthony J. Olszanski, Thomas A. Rado, Alex Starr, Roger B. Cohen	21
5	Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours 2012 ·British Journal of Cancer ·Mark Kozloff, Lainie P. Martin, Maciej Krzakowski, Thomas A. Samuel, Thomas A. Rado, Edurne Arriola, Javier de Castro, Roy S. Herbst, Jamal Tarazi, (unknown), Brad Rosbrook, Michael A. Tortorici, Anthony J. Olszanski, Roger B. Cohen	24
6	Axitinib (AG-013736; AG) combined with chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) and other solid tumors 2009 ·Journal of Clinical Oncology ·Lainie P. Martin, Mark Kozloff, Maciej Krzakowski, Thomas A. Samuel, Thomas A. Rado, Jamal Tarazi, Brad Rosbrook, Michael A. Tortorici, Anthony J. Olszanski, Roger B. Cohen	9
7	PU.1 regulates the expression of the human neutrophil elastase gene 1998 ·Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression ·(unknown), Thomas A. Rado	16
8	Differential expression of two sodium channel subtypes in human brain 1992 ·FEBS Letters ·Chiung‐Mei Lu, Jian Han, Thomas A. Rado, George Bosworth Brown	18
9	Expression and regulation of the cystic fibrosis gene during rat liver regeneration 1992 ·American Journal of Physiology-Cell Physiology ·(unknown), (unknown), (unknown), Thomas A. Rado, Donald M. Miller	16
10	Affinity purification of insoluble recombinant fusion proteins containing glutathione‐S‐transferase 1992 ·Biotechnology and Bioengineering ·John L. Hartman, (unknown), Raymond A. Frizzell, Thomas A. Rado, Dale Benos, Eric J. Sorscher	19
11	Antisense oligonucleotides to CFTR confer a cystic fibrosis phenotype on B lymphocytes 1992 ·American Journal of Physiology-Cell Physiology ·(unknown), (unknown), Thomas A. Rado, James K. Bubien	35
12	Transfection of wild-type CFTR into cystic fibrosis lymphocytes restores chloride conductance at G1 of the cell cycle. 1992 ·The EMBO Journal ·(unknown), James K. Bubien, Mitchell L. Drumm, (unknown), Stephen C. Peiper, Francis S. Collins, Kiaran Kirk, R. A. Frizzell, Thomas A. Rado	37
13	Recombinant synthesis, purification, and nucleotide binding characteristics of the first nucleotide binding domain of the cystic fibrosis gene product. 1992 ·Journal of Biological Chemistry ·John L. Hartman, Zhen Huang, Thomas A. Rado, (unknown), Tamás Jilling, Donald D. Muccio, Eric J. Sorscher	63
14	Regulation of human bone marrow lactoferrin and myeloperoxidase gene expression by tumor necrosis factor-alpha 1991 ·The Journal of Immunology ·C H Srivastava, Thomas A. Rado, (unknown), Hal E. Broxmeyer	26
15	Expression of the human neutrophil elastase gene: Positive and negative transcriptional elements in the 5′ flanking region 1991 ·Biochemical and Biophysical Research Communications ·Jian Han, Tino Unlap, Thomas A. Rado	14
16	Review: Current Approaches to the Molecular and Physiological Basis of Cystic Fibrosis 1989 ·The American Journal of the Medical Sciences ·(unknown), Thomas A. Rado	3
17	Evidence for Host-dependent Modification and Restriction of Bacteriophage DNA in Mycobacterium tuberculosis 1976 ·Journal of General Virology ·Thomas A. Rado, Joseph H. Bates, (unknown)	13
18	World Health Organization studies on bacteriophage typing of mycobacteria. Subdivision of the species Mycobacterium tuberculosis. 1975 ·PubMed ·Thomas A. Rado, Joseph H. Bates, H. W. B. Engel, E. Mankiewicz, (unknown), Y Mizuguchi, L Sŭla	40
19	Phosphotransacetylase from Bacillus subtilis: Purification and physiological studies 1973 ·Biochimica et Biophysica Acta (BBA) - Enzymology ·Thomas A. Rado, James A. Hoch	28
20	Ribosomal Competence and Spore Germination in Fusarium solani 1971 ·Journal of Bacteriology ·Thomas A. Rado, Vincent W. Cochrane	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact